Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GOG Foundation
M.D. Anderson Cancer Center
AstraZeneca
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Incyte Corporation
University of Pittsburgh
Kivu Bioscience Inc.
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
M.D. Anderson Cancer Center
Instil Bio
Kathmandu University School of Medical Sciences
University of Alabama at Birmingham
Genentech, Inc.
M.D. Anderson Cancer Center
AstraZeneca
Instituto do Cancer do Estado de São Paulo
Evopoint Biosciences Inc.
MOMA Therapeutics
Shanghai Shengdi Pharmaceutical Co., Ltd
UNC Lineberger Comprehensive Cancer Center
Kestrel Therapeutics, Inc.
Yuzuncu Yil University
Hangzhou Kangji Weijing Medical Robotics Co., Ltd.
Jiangsu Province Centers for Disease Control and Prevention
Chong Kun Dang Pharmaceutical
National Institutes of Health Clinical Center (CC)
Institut Claudius Regaud